Hair Products, Ingredients, Claims and Evidence — Research Dossier

Cluster: 03 — Products, ingredients, claims, and evidence Research date: September 17, 2026 (status statements are "as of September 2026" unless noted) Scope: Surfactants (sulfates), silicones and EU cyclosiloxane (D4/D5/D6) restrictions; "clean"/"natural"/"non-toxic" claims and U.S. state toxic-free cosmetics and PFAS laws; rosemary oil; biotin and other hair supplements (Nutrafol, collagen, marine protein); topical and low-dose oral minoxidil (information only, no medical advice); benzene in aerosol dry shampoo (recalls, petition, litigation); DevaCurl and WEN class actions; product diversion and counterfeits; viral trends (rice water, shower filters/hard water, purple shampoo, porosity); sustainability claims and the FTC Green Guides.

Method note and limitation of this pass: Research was conducted with WebSearch/WebFetch only. Late in the session the shared web-search budget was exhausted and fetches were rate-limited, so several consumer-trend topics (rice water, hard water/shower filters, purple shampoo, porosity, microplastics, counterfeit seizure data, brand anti-diversion policies) could not be independently verified with fresh primary sources. Those sections are explicitly labeled Low confidence / not verified in this pass and should be sourced before publication claims are strengthened. Nothing below is medical or legal advice.

Key findings

1. The big dry-shampoo benzene recalls were P&G (December 17, 2021) and Unilever (October 18, 2022), not a Unilever 2021 recall. P&G recalled U.S.-made aerosol dry shampoo and dry conditioner sprays under Pantene, Aussie, Herbal Essences, Waterless, Old Spice and Hair Food, saying benzene came "from the propellant" (FDA/P&G, Dec 17, 2021). Unilever recalled Dove, Nexxus, Suave, TIGI (Rockaholic, Bed Head) and TRESemmé aerosol dry shampoos produced before October 2021 (FDA/Unilever, Oct 18, 2022). Both firms said no adverse events had been reported and that daily exposure at detected levels "would not be expected to cause adverse health consequences." Unilever's separate 2021-era note: Unilever recalled two Suave aerosol antiperspirants in March/April 2022 (Unilever). Confidence: High.
2. Valisure's dry-shampoo petition (filed ~Oct 31/Nov 1, 2022) reported benzene in 103 of 148 batches (≈70%) from 34 brands, with 11 lots from 3 brands above 20 ppm and 3 lots above 100 ppm, plus high variability between sprays from the same can (Valisure, Nov 1, 2022; docket FDA-2022-P-2707). This is an independent lab with a commercial testing business; results are not FDA findings. I could not confirm a final FDA response to this petition. Confidence: High (for what Valisure reported); Low (on FDA disposition).
3. Litigation followed but has produced consumer-refund settlements, not proof of harm. Church & Dwight's Batiste/Bare settlement ($2.5M cash + up to $600K vouchers; final approval Oct 18, 2023, N.D. Ill.) included a commitment that propellant would contain ≤2 ppm benzene, with no admission of wrongdoing (AboutLawsuits). A proposed $3.625M Unilever class settlement was reportedly denied preliminary approval without prejudice in February 2026; an $850K IGK settlement was reported (Lawsuit Information Center, Aug 2026 update — plaintiff-firm site, verify against dockets). Confidence: Medium.
4. Rosemary oil evidence rests mainly on one small, 6-month, open comparison trial (Panahi et al., Skinmed 2015; 100 people with androgenetic alopecia, 50 per arm) against 2% minoxidil, not against placebo. Neither group improved at 3 months; both increased hair count at 6 months with no significant difference between groups; scalp itching was more common with minoxidil (PubMed 25842469). Later work includes a 90-person, 90-day trial of branded rosemary blends published in Cureus (June 2025) and narrative reviews (2024, 2026) that call for more research (Cureus 2025; CCID 2024; Dermatology Reports 2026). Confidence: High that evidence is limited.
5. Biotin: FDA has warned since November 28, 2017 (updated November 5, 2019; troponin device list updated June 21, 2022) that high-dose biotin can cause falsely high or low lab results, including falsely low troponin in heart-attack testing (FDA troponin page; Healio, Nov 5, 2019). Reviews in 2024 and 2026 find no good evidence that biotin grows hair in people without deficiency (Yelich et al., JCAD 2024; Moltó-Balado et al., Dermato 2026). Confidence: High.
6. Nutrafol has randomized placebo-controlled data, but the trials are small and company-involved. The 2018 JDD trial enrolled 40 women (26 active, 14 placebo); a co-author was from Nutraceutical Wellness Inc., Nutrafol's maker (JDD 2018). A 2023 JAMA Dermatology systematic review (30 studies) listed Nutrafol, Viviscal and others among supplements with "highest-quality evidence" of potential benefit while noting variable quality (Drake et al.). Unilever took a majority stake in May 2022 (Unilever). Confidence: High.
7. Low-dose oral minoxidil is an off-label, prescription use that dermatologists increasingly employ; topical minoxidil is the FDA-approved form. AAD notes topical minoxidil is FDA-approved for men and women and oral minoxidil is off-label (AAD, 2022); a 2025 review in Am J Clin Dermatol summarizes hypertrichosis (~24%), transient shedding, edema, and rare serious effects such as pericardial effusion, and lists contraindications (Ong, Li, Lipner 2025). Confidence: High.
8. EU cyclosiloxanes: D4 and D5 have been restricted to <0.1% in wash-off cosmetics since January 31, 2020 (Reg. 2018/35). Regulation (EU) 2024/1328 extends restrictions on D4, D5 and D6 to leave-on cosmetics and other consumer/professional products, with the main restriction applying from June 6, 2026 per TÜV, Intertek, CIRS and the Global Silicones Council; some summaries (ChemLinked, Certified Cosmetics) cite June 6, 2027 for certain cosmetic categories. Check the EUR-Lex text for category-specific dates. Confidence: High (2020); Medium (exact 2026 vs 2027 split by category).
9. "Clean," "non-toxic" and "natural" have no legal definition for cosmetics in U.S. federal law; the FTC polices them as ordinary advertising claims. In April 2016 the FTC settled with four companies (and sued a fifth) over "all natural"/"100% natural" claims on products containing synthetic ingredients like dimethicone and phenoxyethanol—including an "All Natural Shampoo" (FTC, Apr 12, 2016). Confidence: High.
10. State laws are now doing what "clean" labels only implied. California's Toxic-Free Cosmetics Act (AB 2762) banned 24 intentionally added substances (incl. formaldehyde, mercury, certain phthalates and 13 PFAS) from January 1, 2025; AB 496 adds 26 more from January 1, 2027 (Keller & Heckman). California AB 2771 bans intentionally added PFAS in cosmetics from January 1, 2025; Colorado, Maryland, Minnesota and Washington also took effect in 2025; Maine and Vermont in 2026; Connecticut in 2028; several more 2027–2032 (Morgan Lewis, Dec 2025). FDA's MoCRA PFAS report (Dec 29, 2025) found 51 PFAS in 1,744 formulations and said data were insufficient to determine safety for most (FDA). Confidence: High (CA dates, FDA report); Medium (multi-state table).
11. WEN and DevaCurl are the defining "hair loss from a cleansing product" class actions—both settled without admission and without a regulator establishing a cause. FDA said in July 2016 it had received 127 adverse event reports directly and that the companies had received 21,000+ complaints, but it had not determined a cause (NBC/FDA, July 2016). WEN settled for $26.25M (C.D. Cal.) (Law360 via firm site, May 2017). DevaCurl settled for $5.2M, final approval January 3, 2022 (S.D.N.Y.) (Bloomberg Law). Confidence: High.
12. Sulfates are effective cleansers that can irritate at higher concentrations and longer contact; the evidence that "sulfate-free" alone prevents color fading is thin. The Cosmetic Ingredient Review found SLS/ALS safe in rinse-off products and limited leave-on use to 1% because irritation rises with concentration and contact time (CIR). Supplier research (Solvay, 2013) found water itself, prior bleaching/perming, UV and heat all drive fading, and formulation (e.g., deposited silicones/cationic polymers) mattered (Cosmetics & Toiletries). Confidence: Medium.

1. Surfactants: sulfates vs. alternatives

What they are. Sodium lauryl sulfate (SLS), ammonium lauryl sulfate (ALS) and sodium laureth sulfate (SLES) are anionic surfactants that lift oil and dirt and create foam. "Sulfate-free" shampoos substitute other surfactants—e.g., sulfonates and olefin sulfonates, isethionates, taurates, glutamates/sarcosinates, betaines and glucosides. "Sulfate-free" does not automatically mean "mild"; some alternatives (e.g., sodium C14-16 olefin sulfonate) are also strong cleansers. (General formulation knowledge; Medium confidence.)

Irritation evidence. The CIR's 1983 safety assessment (the basis of its still-cited conclusion) found SLS and ALS "appear to be safe in formulations designed for discontinuous, brief use followed by thorough rinsing," and should not exceed 1% in leave-on products; irritation increased with concentration and duration, with patch-test irritation at roughly ≥2% (CIR alert summary; J Am Coll Toxicol 1983). The CIR also found SLS not carcinogenic in animal studies—countering persistent "sulfates cause cancer" posts. SLS is widely used in dermatology research as a model irritant for patch testing, which is why it can bother people with sensitive or eczema-prone scalps. Ethoxylation (SLES) generally reduces irritation compared with SLS, but SLES may contain trace 1,4-dioxane as a manufacturing by-product—a separate regulatory issue (New York's 1,4-dioxane limits for cosmetics; not re-verified in this pass).

Color fading. The mechanism claim—strong surfactants swell the cuticle and wash out oxidative dye molecules faster—is plausible, but public, independent head-to-head consumer data are scarce. A Solvay study published in Cosmetics & Toiletries (Bendejacq, May 30, 2013) found that water alone contributes significantly to wash-out fading; damage from bleaching then perming led to ~50% color loss after five shampoos versus ~30% in the reverse order; and adding deposited silicones (e.g., 2% dimethicone) with cationic polymers improved color retention (C&T). Limitation: supplier-sponsored lab work on hair tresses. Takeaway: wash frequency, water temperature, prior damage, UV and heat probably matter as much as the sulfate question.

Textured and curly hair. Curly and coily hair tends to be drier at the ends because sebum travels less easily down the shaft; many stylists recommend gentler cleansers or co-washing. This is largely clinical/trade consensus, not trial-based. The WEN and DevaCurl litigation (Section 8) is a reminder that "gentle/no-sulfate" cleansing products are not risk-free.

2. Silicones and buildup; EU D4/D5/D6

Function. Dimethicone, amodimethicone and similar silicones reduce friction, detangle, add shine and provide some heat and color-wash protection (see Solvay data above). Water-soluble variants (e.g., PEG-modified dimethicones) rinse easily; heavier non-volatile silicones can accumulate on hair, especially with low-lather cleansers or co-washing. Amodimethicone binds preferentially to damaged (negatively charged) areas. Independent peer-reviewed evidence on "buildup" causing damage is thin: the claim is mostly about feel (limpness, coating) rather than harm. A review in the International Journal of Trichology summarizes silicone function in conditioners (Gavazzoni Dias, 2015). Confidence: Medium.

Environmental rather than health restriction. The EU restrictions on cyclic siloxanes (D4 = octamethylcyclotetrasiloxane; D5 = decamethylcyclopentasiloxane, often labeled "cyclopentasiloxane"; D6 = dodecamethylcyclohexasiloxane) are driven by their persistence and bioaccumulation (vPvB/PBT, SVHC status), not by evidence of harm to users of hair products.

• Commission Regulation (EU) 2018/35: D4 and D5 ≥0.1% w/w banned in wash-off cosmetics placed on the market after January 31, 2020 (Cosmetics & Toiletries; Global Silicones Council).
• Commission Regulation (EU) 2024/1328 (published May 16–17, 2024, amending REACH Annex XVII entry 70): D4, D5, D6 ≥0.1% w/w restricted in leave-on cosmetics and other consumer/professional products (dry cleaning, waxes, polishes, washing/cleaning products), applying "after 6 June 2026," with derogations (e.g., D5/D6 in scar/wound/stoma care devices; D5 in closed dry-cleaning systems) (Intertek; TÜV Rheinland; CIRS). ChemLinked and Certified Cosmetics describe a transitional date of June 6, 2027 for leave-on/D6 rinse-off cosmetics (ChemLinked; Certified Cosmetics). Unresolved: sources disagree on whether all leave-on cosmetics were covered from June 2026 or given until June 2027; consult EUR-Lex 2024/1328 before publishing a single date. As of September 2026, at least the June 6, 2026 restriction is in application for covered categories.
• Omnibus VII (Reg. (EU) 2025/877) added 22 CMR substances to the cosmetics ban list from September 1, 2025 (Obelis); I could not confirm whether D4 is on that list in this pass.

Practical meaning for U.S. consumers: U.S. law does not restrict D4/D5 in cosmetics; multinational brands often reformulate globally. "Silicone-free" is a preference claim, not a safety claim.

3. "Clean," "natural," "non-toxic" and the law

• No federal definition. Neither the FD&C Act nor MoCRA (2022) defines "clean," "non-toxic," "natural" or "salon-exclusive" for cosmetics (FDA MoCRA page). Retailer programs (e.g., "Clean at Sephora," "Conscious Beauty at Ulta") are private standards that mainly list excluded ingredients.
• FTC stance. Under Section 5 of the FTC Act, claims must be truthful and substantiated. The April 12, 2016 actions targeted Trans-India Products (ShiKai), Erickson Marketing Group (Rocky Mountain Sunscreen), ABS Consumer Products (EDEN BodyWorks—"Jojoba Monoi All Natural Shampoo," "Coconut Shea All Natural Styling Elixir"), Beyond Coastal, and California Naturel; the products contained synthetic ingredients such as dimethicone, polyquaternium-7/-37, phenoxyethanol and caprylyl glycol (FTC press release; FTC business blog). "Non-toxic" is problematic because toxicity depends on dose and exposure; private class actions over "clean"/"non-toxic" claims have grown (Duane Morris).
• State toxic-free cosmetics laws.
  • California AB 2762 (Toxic-Free Cosmetics Act, 2020): bans 24 intentionally added ingredients from January 1, 2025, including formaldehyde, paraformaldehyde, mercury, dibutyl/diethylhexyl phthalate, isobutyl-/isopropylparaben, m- and o-phenylenediamine and 13 PFAS; trace impurities that are technically unavoidable are allowed. AB 496 (signed October 8, 2023) adds 26 more (e.g., styrene, acetaldehyde, sodium perborate) from January 1, 2027 (Keller & Heckman; Sheppard Mullin). Hair products are within scope.
  • Washington Toxic-Free Cosmetics Act (HB 1047, 2023): restrictions on intentionally added formaldehyde and other chemical classes from January 1, 2025; Ecology's rule (August 28, 2025) restricts 25 formaldehyde-releasing chemicals from January 1, 2027, with retail sell-through to December 31, 2027; hair treatments and shampoos, and occupational exposure of stylists, were cited (WA Ecology).
• Formaldehyde straighteners are covered in a separate cluster; FDA's proposed federal ban has been repeatedly delayed (not re-verified here).

4. PFAS and microplastics

• FDA MoCRA report (December 29, 2025): 51 PFAS identified in 1,744 cosmetic formulations; FDA assessed the 25 most-used (≈96% of intentional use), found 5 of low concern, 1 with potential concern and significant uncertainty, and insufficient data for most (FDA press release; Covington). No federal ban followed as of this research (Medium confidence).
• State PFAS cosmetics bans (intentionally added PFAS unless noted) per Morgan Lewis (Dec 2025) and Holland & Knight (Aug 2025):
  • January 1, 2025: California (AB 2771), Colorado (HB 22-1345), Maryland (HB 643), Minnesota (Amara's Law, HF 2310; rules finalized December 8, 2025), Washington (HB 1047; "intentionally added" definition from 2027).
  • January 1, 2026: Maine, Vermont (S.25).
  • Connecticut: labeling/notification July 1, 2026; prohibition January 1, 2028.
  • 2027: New Hampshire, New Jersey, Oregon, Rhode Island; 2028: New Mexico; 2032: Illinois (dates as summarized by Morgan Lewis; verify statutes).
  • Where PFAS show up in hair care: some styling, anti-frizz and heat-protectant products (e.g., "PTFE," "perfluoro-/polyfluoro-" INCI names). Check labels for "fluoro" terms (Medium confidence).
• EU: A universal PFAS restriction under REACH remains at proposal stage (as of sources reviewed); intentionally added microplastics restriction (Reg. (EU) 2023/2055) has phased deadlines for rinse-off (2027) and leave-on (2029) cosmetics—not re-verified in this pass; Low confidence.

5. Rosemary oil

The 2015 trial. Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. "Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial." Skinmed 2015;13(1):15–21 (PubMed 25842469).

• Design: 100 patients with AGA randomized to rosemary oil (n=50) or minoxidil 2% (n=50) for 6 months; microphotographic hair counts at 0, 3 and 6 months.
• Results: no significant change at 3 months in either group; both significant increases at 6 months vs baseline; no significant between-group difference; scalp itching increased in both and was more frequent with minoxidil.
• Limitations (from abstract and design): no placebo arm (so "no difference" cannot show either worked beyond natural variation or regression); the comparator was the lower-strength 2% minoxidil; non-inferiority not formally established; small sample; abstract does not specify blinding, rosemary preparation/concentration details, sex distribution or effect sizes; single study from one research group; not replicated at scale. Early-2020s social media often describes the result as "rosemary works as well as minoxidil," which overstates it. Later evidence.
• Patel M et al., Cureus, June 13, 2025: 90 participants, 90 days, three arms—rosemary-lavender oil, rosemary-castor oil, coconut-oil control; reported ~58% and ~48% increases in hair growth rate and improvements in thickness/density (Cureus; Tressless summary). Limitations: trademarked product (PDF hosted by Novobliss, suggesting commercial involvement—funding not confirmed in this pass), short duration, blends make it impossible to isolate rosemary, Cureus is a fast-review open-access journal.
• Bin Rubaian et al., Clinical, Cosmetic and Investigational Dermatology, Nov 5, 2024: narrative review; says finasteride and minoxidil are the only FDA-approved AGA drugs and further research is needed on herbals (PMC11549889).
• Almutairi et al., Dermatology Reports, Feb 2, 2026: narrative review; calls rosemary leaf extract a possible alternative but emphasizes need for mechanistic and long-term data (Dermatology Reports).
• Preclinical: mouse studies of rosemary leaf extract (e.g., anti-androgen/5α-reductase activity) are often cited; not re-fetched here. Safety: Essential oils can cause irritant or allergic contact dermatitis, especially undiluted; people with scalp conditions should consult a dermatologist. Overall confidence: High that evidence is preliminary; Low for any specific efficacy magnitude.

6. Biotin

• FDA safety communication. Issued November 28, 2017; updated November 5, 2019, noting continued adverse event reports and at least one death linked to falsely low troponin (the death figure appears in FDA's 2019 update per contemporaneous coverage; the fetched Healio summary did not restate it—treat as Medium). FDA's troponin assay page (last updated June 21, 2022) lists 18 cleared troponin devices still susceptible to interference (FDA). Hair/skin/nail supplements can contain biotin up to ~650 times the daily recommended intake (Healio). Affected tests can include thyroid, hormone and cardiac immunoassays that use biotin–streptavidin chemistry. Advice: tell clinicians and the lab about any biotin before bloodwork.
• Efficacy. Patel, Swink & Castelo-Soccio, Skin Appendage Disorders 2017, found reported benefit only in people with underlying deficiency or specific conditions (Karger). Yelich et al. (JCAD, August 2024) found only three eligible studies; the best (double-blind, placebo-controlled) showed "no difference" (PubMed 39148962). Moltó-Balado et al. (Dermato, May 4, 2026), 10 studies: biotin monotherapy "did not show consistent benefit" and is not supported without documented deficiency (MDPI). AAD: vitamins only if a deficiency is confirmed (AAD). Confidence: High.

7. Other supplements: Nutrafol, marine protein (Viviscal), collagen

• Nutrafol. Ablon G, Kogan S. J Drugs Dermatol May 2018: 6-month RCT in 40 women with self-perceived thinning (26 active, 14 placebo); reported significant increases in terminal and vellus hair counts at days 90 and 180 (P<0.009) (JDD). Co-author Kogan was affiliated with Nutraceutical Wellness Inc. (Nutrafol's company). Later trials include menopausal women (JDD 2021) and a single-blind, diverse-ethnicity study of men and women (PubMed 35309272); both company-associated (details not re-fetched). Unilever acquired a majority stake on May 30, 2022 (previously 13.2% via Unilever Ventures); marketing claims "#1 dermatologist recommended hair growth brand" based on an IQVIA survey (Unilever). Nutrafol is a dietary supplement—not FDA-approved to treat hair loss.
• Systematic review. Drake L et al., JAMA Dermatology 2023;159(1):79–86 (online Nov 30, 2022): 30 studies (17 RCTs), people without known deficiency; highest-quality evidence suggested potential benefit for Viviscal (marine protein complex), Nourkrin, Nutrafol, Lambdapil, Pantogar, capsaicin/isoflavone, omega-3/6 with antioxidants, apple nutraceutical, total glucosides of paeony/compound glycyrrhizin, zinc, tocotrienol and pumpkin seed oil; adverse effects rare and mild; recommends shared decision-making (JAMA Derm; MedicalXpress). Note: many included trials were manufacturer-funded; some multi-ingredient supplements contain biotin, vitamin A or selenium that can be harmful in excess. Confidence: High.
• Collagen. Evidence specific to collagen peptides for hair growth is sparse; one 3-month assessor-blinded randomized study tested a combined supplement (amino acids, iron, selenium, marine hydrolyzed collagen), so collagen's own effect can't be isolated (Milani et al., Skin Res Technol 2023). Confidence: Medium that evidence is weak.

8. Minoxidil and low-dose oral minoxidil (LDOM) — information, not advice

• Topical minoxidil (2% and 5%) is FDA-approved OTC for hereditary hair loss; results usually need months of consistent use and stopping typically reverses gains (AAD). Oral finasteride is approved for men; spironolactone is used off-label in women.
• LDOM: originally a blood-pressure drug (with boxed warnings at antihypertensive doses); used off-label in much lower doses for AGA, telogen effluvium and other alopecias. A 2025 Am J Clin Dermatol review (Ong, Li, Lipner; published Oct 21, 2025) reports comparable efficacy to topical with better adherence, hypertrichosis ~24% (dose-dependent), transient shedding 16–22%, mild peripheral edema ~2%, rare pericardial effusion; contraindications include pericardial disease, uncontrolled hypertension and pregnancy (Springer). A multicenter JAAD study of 1,404 patients (Vañó-Galván et al., 2024) is widely cited on safety (JAAD); JAAD also published 2025 "summation and recommendations" on topical and oral minoxidil (JAAD 2025). Mainstream media coverage from about 2022 onward helped popularize LDOM (specific articles not re-verified in this pass). Posts must not give dosing; direct readers to a board-certified dermatologist.

9. Benzene in aerosol dry shampoo

Why it happened. Benzene is not an ingredient. The companies attributed it to contaminated hydrocarbon propellants (butane/isobutane/propane) used to spray the product. Benzene is a known human carcinogen (IARC Group 1) linked to leukemia and other blood disorders; risk depends on dose and duration. Timeline.

• 2021 (May–Nov): Valisure petitions on benzene in sunscreens and body sprays; P&G recalls Old Spice and Secret aerosol antiperspirants (November 2021, per Cosmetics & Toiletries).
• December 17, 2021: P&G recalls aerosol dry conditioner and dry shampoo sprays (Pantene, Aussie, Herbal Essences, Waterless, Old Spice, Hair Food), ~2 dozen SKUs; consumers check the first four digits of the production code on the can bottom against P&G tables; reimbursement via brand websites or 1-888-674-3631 (FDA; Herbal Essences recall page).
• March 31–April 1, 2022: Unilever recalls two Suave 24-Hour Protection aerosol antiperspirants (Unilever; NPR).
• October 18, 2022: Unilever recalls select aerosol dry shampoos (Dove, Nexxus, Suave, TIGI Rockaholic and Bed Head, TRESemmé) made before October 2021; UPC list and reimbursement at UnileverRecall.com or (877) 270-7412 (FDA).
• October 31/November 1, 2022: Valisure Citizen Petition #7 on dry shampoo (148 batches, 34 brands, 70% with detectable benzene; 3 lots >100 ppm) (Valisure). Poison Control summarizes that samples from some lots of Not Your Mother's, Sun Bum, OGX, Batiste and Paul Mitchell tested positive while other samples from the same brands did not, and that "there is no evidence that occasional use of dry shampoo is harmful" (Poison Control).
• 2023: Batiste/Bare class settlement final approval October 18, 2023 (≤2 ppm benzene propellant commitment; no admission). Whether Church & Dwight issued a formal recall is not confirmed—AboutLawsuits says so, but the Poison Control and FDA sources reviewed list no Batiste recall; treat as unverified.
• 2024: Paul Mitchell benzene class claims dismissed (September 2024) for failure to tie purchased bottles to contaminated batches (Lawsuit Information Center); IGK settlement ($850K) for purchases before April 23, 2024.
• February 2026: Unilever proposed $3.625M class settlement denied preliminary approval without prejudice (reported by plaintiff-firm site; Medium).
• Later recalls: I could not confirm any new dry shampoo benzene recall in 2024–2026 in FDA's database during this pass (search budget exhausted). FDA's benzene guidance for drugs sets a 2 ppm limit where benzene use is unavoidable (FDA drug FAQ); cosmetics have no specific numeric benzene limit in U.S. law. MoCRA (effective Dec 29, 2023 for many provisions) gave FDA mandatory recall authority for cosmetics. How to check products: find the brand recall page (P&G production codes; Unilever UPCs), search FDA's Recalls, Market Withdrawals & Safety Alerts database, and check the purchase/manufacture date; consider non-aerosol (powder) dry shampoos if concerned; use aerosols in ventilated areas. Salon professionals using aerosols all day have higher cumulative exposure than consumers (see occupational cluster).

10. DevaCurl and WEN

• WEN by Chaz Dean (Guthy-Renker): FDA opened an investigation (publicized July 19, 2016) after 127 direct adverse event reports—the most FDA had received for a hair-cleansing product—and companies' reports of 21,000+ consumer complaints of hair loss, breakage, itching and rash; FDA had "not yet determined a possible cause" (NBC Washington). Class action in C.D. Cal. (Judge Otis D. Wright II) settled for $26.25M covering purchases Nov 1, 2007–Aug 1, 2016; $25 flat claims or up to $20,000 for documented injury; defendants denied liability (firm-posted Law360, May 2, 2017; Wikipedia). The episode fed calls for FDA mandatory recall authority, ultimately enacted in MoCRA 2022.
• DevaCurl (Deva Concepts; owned by Henkel since 2019): In re Deva Concepts Products Liability Litigation (S.D.N.Y., Judge Gregory H. Woods). $5.2M settlement; final approval January 3, 2022; class of U.S. purchasers/users Feb 8, 2008–Aug 29, 2021; Tier 1 up to $20 without proof; Tier 2 up to $18,000 plus $1,000 expenses with medical/photo documentation; 54,000+ claims; denial of wrongdoing (Bloomberg Law; Top Class Actions). Do not state that either product was proven to cause hair loss.

11. Product diversion and counterfeits — Low confidence / partially verified

• Definition: "Diversion" is when professional-only products reach unauthorized retailers (drugstores, discount sites, third-party marketplace sellers) outside the brand's salon distribution agreements. Brands including Redken, Biolage, OPI, amika and SalonCentric publish anti-diversion policies stating they cannot guarantee authenticity, freshness or safety of products sold outside authorized channels (Redken; Biolage; OPI; amika; SalonCentric) — these pages were identified by search but could not be fetched in this pass, so their exact wording is not quoted.
• Risks commonly cited: old or heat-exposed stock, tampered or refilled bottles, removed batch codes (to prevent tracing), counterfeits with unknown ingredients.
• MoCRA relevance: labels must (from Dec 29, 2024 under MoCRA as enacted) include a U.S. domestic address/phone/website for adverse event reporting; missing responsible-person contact info is a red flag (MoCRA labeling timing not re-verified in this pass; Medium).
• Data gaps: I could not retrieve U.S. CBP seizure statistics for counterfeit cosmetics or brand-specific counterfeit lawsuits for hair care in this pass.

12. Viral trends — Low confidence / not verified in this pass

The following summarize widely reported research that I could not re-fetch in this session; blog post 16 labels these as limited evidence and avoids specific figures that were not verified.

• Rice water: Studies commonly cited are small lab/tress studies on inositol and rice-water fractions (e.g., Inamasu et al., IFSCC 2010) — no robust human clinical trials of DIY fermented rice water for growth identified. Plausible benefits: temporary surface smoothing; risks: protein/starch buildup feel, scalp irritation, bacterial growth in long-fermented batches.
• Scalp oiling: Coconut oil pre-wash reduces protein loss in lab studies on hair fibers (Rele & Mohile, J Cosmet Sci 2003 — not re-verified). Heavy oiling may aggravate seborrheic dermatitis because Malassezia yeast metabolize some oils (dermatology consensus; not re-verified).
• Hard water / shower filters: Small studies (e.g., in International Journal of Trichology) on hard vs distilled water show mixed results for hair strength; minerals (calcium, magnesium, copper, iron) can deposit on hair and affect color and feel; independent evidence that consumer vitamin-C/KDF shower filters meaningfully change hair outcomes is lacking. Chlorine removal claims vary by filter certification (NSF/ANSI standards).
• Purple shampoo: Uses violet dyes to neutralize yellow (color theory); it's a deposit-only toner effect that washes out; overuse can leave lilac tint on porous blonde/gray hair. Not a "strengthening" product.
• Porosity & protein–moisture balance: Porosity (cuticle condition and water uptake) is measurable in labs; the popular "float test" is unreliable (surface tension, oils and products affect it). "Protein overload" is a stylist-community concept with little formal research; bleached/relaxed hair does lose protein (keratin damage) and benefits from conditioning.
• Bond-builders (e.g., maleic acid, bis-aminopropyl diglycol dimaleate) — covered in another cluster.

13. Refill, waterless and sustainability claims

• FTC Green Guides (16 C.F.R. Part 260) were last revised in 2012; the FTC requested comment on updates in December 2022 and held a recyclability workshop in May 2023; as of February 2025 FTC said it had "nothing new to share" (Packaging Dive). I could not confirm any final revised Green Guides as of September 2026 (Low confidence on current status; appears still pending).
• Guides' principles: avoid unqualified general claims ("eco-friendly," "green"); "recyclable" requires substantial majority (60%) access to recycling; "compostable" and "degradable" require competent evidence; qualify refill and "plastic-free" claims.
• California SB 343 (2021) restricts use of the chasing-arrows/recyclable claims unless materials meet CalRecycle criteria; implementation runs 18 months after CalRecycle's material characterization report (expected 2025) (Packaging Dive). Exact compliance date not re-verified.
• "Waterless" products (bars, powders) reduce shipping weight but lifecycle-assessment evidence is product-specific. Refill schemes help only if refills are actually used; independent LCAs are rare.
• EU Empowering Consumers for the Green Transition Directive (2024/825) bans generic environmental claims from September 27, 2026 (not re-verified in this pass; Medium).

Open questions / couldn't verify

1. Exact category split between June 6, 2026 and June 6, 2027 under Reg. (EU) 2024/1328 for leave-on cosmetics; whether D4 is on the Omnibus VII Annex II list.
2. FDA's formal response (if any) to Valisure's dry shampoo petition FDA-2022-P-2707.
3. Any dry-shampoo benzene recall after October 2022 (none found, but search could not be completed).
4. Whether Batiste was formally recalled (conflicting secondary sources).
5. Status of the Unilever dry-shampoo class settlement after February 2026.
6. Funding/sponsor of the 2025 Cureus rosemary trial.
7. Current status of FTC Green Guides revision.
8. Primary sources for rice water, hard water, porosity, oiling and purple shampoo evidence; CBP counterfeit cosmetic seizure data; brand anti-diversion policy wording.
9. EU microplastics restriction deadlines for cosmetics and the EU green-claims directive date.

Source list